Inhibition of human immunodeficiency virus type 1 replication in acutely and chronically infected cells by EM2487, a novel substance produced by a Streptomyces species

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 10, 1999, Pages 2350-2355

  Baba, Masanori ^a   Okamoto, Mika ^a   Takeuchi, Hitoshi ^b  

^a KAGOSHIMA UNIVERSITY   (Japan)

^b EISAI CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

8 DIFLUOROMETHOXY 1 ETHYL 6 FLUORO 1,4 DIHYDRO 7 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL] 4 QUINOLONE 3 CARBOXYLIC ACID; ANTIVIRUS AGENT; EM 2487; EMIVIRINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LAMIVUDINE; MESSENGER RNA; NELFINAVIR; TRANSACTIVATOR PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIRUS DNA; [7 CHLORO 5 (1H PYRROL 2 YL) 3H BENZO[E][1,4]DIAZEPIN 2 YL]METHYLAMINE;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DNA SYNTHESIS; DRUG MECHANISM; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG TERMINAL REPEAT; MONONUCLEAR CELL; PRIORITY JOURNAL; PROVIRUS; REPORTER GENE; RNA SYNTHESIS; STREPTOMYCES; T LYMPHOCYTE; VIRUS REPLICATION; VIRUS TRANSCRIPTION;

EID: 0032870371     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.10.2350     Document Type: Article

References (36)

1. Baba, M., E. De Clercq, H. Tanaka, M. Ubasawa, H. Takashima, K. Sekiya, I. Nitta, K. Umezu, H. Nakashima, S. Mori, S. Shigeta, R. T. Walker, and T. Miyasaka. 1991. Potent and selective inhibition of human immunodeficiency virus type 1 (HIV-1) by 5-ethyl-6-phenylthiouracil derivatives through their interaction with the HIV-1 reverse transcriptase. Proc. Natl. Acad. Sci. USA 88:2356-2360.
2. Baba, M., M. Okamoto, M. Kawamura, M. Makino, T. Higashida, T. Takashi, Y. Kimura, T. Ikeuchi, T. Tetsuka, and T. Okamoto. 1998. Inhibition of human immunodeficiency virus type 1 replication and cytokine production by fluoroquinoline derivatives. Mol. Pharmacol. 53:1097-1103.
3. Baba, M., M. Okamoto, M. Makino, Y. Kimura, T. Ikeuchi, T. Sakaguchi, and T. Okamoto. 1997. Potent and selective inhibition of human immunodeficiency virus type 1 transcription by piperazinyloxoquinoline derivatives. Antimicrob. Agents Chemother. 41:1250-1255.
4. Baba, M., S. Shigeta, S. Yuasa, H. Takashima, K. Sekiya, M. Ubasawa, H. Tanaka, T. Miyasaka, R. T. Walker, and E. De Clercq. 1994. Preclinical evaluation of MKC-442, a highly potent and specific inhibitor of human immunodeficiency virus type 1 in vitro. Antimicrob. Agents Chemother. 38:688-692.
5. Bauer, H. M., Y. Ting, C. E. Greer, J. C. Chambers, C. J. Tashiro, J. Chimera, A. Reingold, and M. M. Manos. 1991. Genital human papillomavirus infection in female university students as determined by a PCR-based method. JAMA 265:472-477.
6. Braddock, M., P. Cannon, M. Muckenthaler, A. J. Kingsman, and S. M. Kingsman. 1994. Inhibition of human immunodeficiency virus type 1 Tat-dependent activation of translation in Xenopus oocytes by the benzodiazepine Ro24-7429 requires trans-activation response element loop sequences. J. Virol. 68:25-33.
7. + cell model of chronic infection. J. Virol. 65:4645-4653.
8. Carpenter, C. C. J., M. A. Fischl, S. M. Hammer, M. S. Hirsch, D. M. Jacobsen, D. A. Katzenstein, J. S. G. Montaner, D. D. Richman, M. S. Saag, R. T. Schooley, M. A. Thompson, S. Vella, P. G. Yeni, and P. A. Volberding. 1998. Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. JAMA 280:78-86.
9. Clouse, K. A., D. Powell, I. Washington, G. Poli, K. Strebel, W. Farrar, B. Barstad, J. Kovacs, A. S. Fauci, and T. M. Folks. 1989. Monokine regulation of human immunodeficiency virus-1 expression in a chronically infected human T cell clone. J. Immunol. 142:431-438.
10. Cujec, T. P., H. Okamoto, K. Fujinaga, J. Meyer, H. Chamerlin, D. O. Morgan, and M. Peterlin. 1997. The HIV transactivator TAT binds to the CDK-activating kinase and activates the phosphorylation of the carboxy-terminal domain of RNA polymerase II. Genes Dev. 11:2645-2657.
11. Cupelli, L. A., and M.-C. Hsu. 1995. The human immunodeficiency virus type 1 Tat antagonist, Ro 5-3335, predominantly inhibits transcription initiation from the viral promoter. J. Virol. 69:2640-2643.
12. Deeks, S. G., M. Smith, M. Holodniy, and J. O. Kahn. 1997. HIV-1 protease inhibitors. A review for clinicians. JAMA 277:145-153.
13. Finzi, D., M. Hermankova, T. Pierson, L. M. Carruth, C. Back, R. E. Chaisson, T. C. Quinn, K. Chadwick, J. Margolick, R. Brookmeyer, J. Gallant, M. Markowitz, D. D. Ho, D. D. Richman, and R. F. Siliciano. 1997. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278:1295-1300.
14. Goto, M., K. Yamada, K. Katayama, and I. Tanaka. 1996. Inhibitory effect of E3330, a novel quinone derivative able to suppress tumor necrosis factor-α generation, on activation of nuclear factor-κB. Mol. Pharmacol. 49: 860-873.
15. Griffin, G. E., K. Leung, T. M. Folks, S. Kunkel, and G. Nabel. 1989. Activation of HIV gene expression during monocyte differentiation by induction of NF-κB. Nature 339:70-73.
16. Hamy, F., E. R. Felder, G. Heizman, J. Lazdins, F. Aboul-Ela, G. Varani, J. Karn, and T. Klimkait. 1997. An inhibitor of the Tat/TAR RNA interaction that effectively suppresses HIV-1 replication. Proc. Natl. Acad. Sci. USA 94:3548-3553.
17. Havlir, D. V., and D. D. Richman. 1996. Viral dynamics of HIV: implications for drug development and therapeutic strategies. Ann. Intern. Med. 124: 984-994.
18. Hsu, M.-C., U. Dhingra, J. V. Earley, M. Holley, D. Keith, C. M. Nalin, A. R. Richou, A. D. Schutt, S. Y. Tam, M. J. Potash, D. J. Volsky, and D. D. Richman. 1993. Inhibition of type 1 human immunodeficiency virus replication by a Tat antagonist to which the virus remains sensitive after prolonged exposure in vitro. Proc. Natl. Acad. Sci. USA 90:6395-6399.
19. Hsu, M.-C., A. D. Schutt, M. Holly, L. W. Slice, M. I. Sherman, D. D. Richman, M. J. Potash, and D. J. Volsky. 1991. Inhibition of HIV replication in acute and chronic infections in vitro by a Tat antagonist. Science 254: 1799-1802.
20. Kikukawa, R., Y. Koyanagi, S. Harada, N. Kobayashi, M. Hatanaka, and N. Yamamoto. 1986. Differential susceptibility to the acquired immunodeficiency syndrome retrovirus in clone cells of human leukemic T-cell line Molt-4. J. Virol. 57:1159-1162.
21. Miyoshi, I., H. Taguchi, I. Kubonishi, S. Yoshimoto, Y. Ohtsuki, Y. Shiraishi, and T. Akagi. 1982. Type C virus-producing cell lines derived from adult T cell leukemia. Gann Monogr. 28:219-228.
22. Nabel, G., and D. Baltimore. 1987. An inducible transcription factor activates expression of human immunodeficiency virus in T cells. Nature 326: 711-713.
23. Ou, C.-Y., S. Kwok, S. W. Mitchell, D. H. Mack, J. J. Sninsky, J. W. Krebs, P. Feorino, D. Warfield, and G. Schochetman. 1988. DNA amplification for direct detection of HIV-1 in DNA of peripheral blood mononuclear cells. Science 239:295-297.
24. Pauwels, R., K. Andries, J. Desmyter, D. Schols, M. J. Kukla, H. J. Breslin, A. Raeymaeckers, J. Van Gelder, R. Woestenborghs, J. Heykants, K. Schellekens, M. A. C. Janssen, E. De Clercq, and P. A. J. Janssen. 1990. Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature 343:470-474.
25. Pauwels, R., J. Balzarini, M. Baba, R. Snoeck, D. Schols, P. Herdewijn, J. Desmyter, and E. De Clercq. 1988. Rapid and automated tetrazolium-based colorimetric assay for detection of anti-HIV compounds. J. Virol. Methods 20:309-321.
26. Perelson, A. S., A. U. Neumann, M. Markowitz, J. M. Leonard, and D. D. Ho. 1996. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 271:1582-1586.
27. Ratner, L., A. Fisher, L. L. Jagodzinski, H. Mitsuya, R. S. Liou, R. C. Gallo, and F. Wong-Staal. 1987. Complete nucleotide sequences of functional clones of the AIDS virus. AIDS Res. Hum. Retroviruses 3:57-69.
28. 27a. Takeuchi, H., et al. Unpublished data.
29. Veschambre, P., P. Simard, and P. Jalinot. 1995. Evidence for functional interaction between the HIV-1 Tat transactivator and the TATA box binding protein in vivo. J. Mol. Biol. 250:169-180.
30. Wei, P., M. E. Garber, S.-M. Fang, W. H. Fischer, and K. A. Jones. 1998. A novel CDK-9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA. Cell 92:451-462.
31. Witvrouw, M., D. Daelemans, C. Pannecouque, J. Neyts, P. Andrei, R. Snoeck, A.-M. Vandamme, J. Balzarini, J. Desmyter, M. Baba, and E. De Clercq. 1998. Broad-spectrum antiviral activity and mechanism of antiviral action of the fluoroquinoline derivative K-12. Antiviral Chem. Chemother. 9: 403-411.
32. Witvrouw, M., R. Pauwels, A. Vandamme, D. Schols, D. Reymen, N. Yamamoto, J. Desmyter, and E. De Clercq. 1992. Cell type-specific anti-human immunodeficiency virus type 1 activity of the transcription inhibitor Ro5-3335. Antimicrob. Agents Chemother. 36:2628-2633.
33. Wong, J. K., M. Hezareh, H. F. Günthard, D. V. Havlir, C. C. Ignacio, C. A. Spina, and D. D. Richman. 1997. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278:1921-1925.
34. Yang, X., C. H. Herrmann, and A. P. Rice. 1996. The human immunodeficiency virus Tat proteins specifically associate with TAK in vivo and require the carboxyl-terminal domain of RNA polymerase II for function. J. Virol. 70:4576-4584.
35. Zhou, Q., and P. A. Sharp. 1996. Tat-SF1: cofactor for stimulation of transcriptional elongation by HIV-1 Tat. Science 274:605-610.
36. Zhu, Y., T. Pe'ery, J. Peng, Y. Ramanathan, N. Marshall, T. Marshall, B. Amendt, M. B. Mathews, and D. H. Price. 1997. Transcription elongation factor P-TEFb is required for HIV-1 Tat transactivation in vitro. Genes Dev. 11:2622-2632.